Lorraine M. Rusch PhD

Dr. Rusch is an executive level business development professional and drug development scientist specializing in early clinical development services at Vince and Associates Clinical Research, providing a consultative service tailored to the needs of biotechnology and pharma clients. Dr. Rusch earned her Ph.D. in Laboratory Medicine and Bioanalytical Chemistry from the Cleveland Clinic Foundation/Cleveland State University Consortium. She has significant drug development expertise in the biotechnology industry as well as operational expertise in early clinical development contract research organizational leadership. Dr. Rusch provided clinical pharmacology and metabolism expertise on many pre-IND drug development teams, with prior preclinical and early clinical responsibilities for Merck’s Zolinza™, a first-in-class histone deacetyylase inhibitor (HDAC) currently approved for the treatment of cutaneous T-cell lymphoma and under study for additional indications. Dr. Rusch’s current interest is the creation of viable strategies for clients focused in achieving Proof of Concept (POC) in Phase I/IIa by use of adaptive clinical trials involving both healthy normal subjects and patient populations, having established this capability at Vince and Associates Clinical Research, a premier facility with a proven track record of POC execution